Skip to content
DataLookout
Menu

NCT07824167

The EMBRACE Study: Enflonsia Monoclonal in Babies - RSV Antibody Concentration Evaluation

StatusNot Yet Recruiting
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Notable Start date pushed from Sep 2026 to Nov 2026
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Geometric mean concentration (GMC) of serum RSV pre-fusion (preF) binding IgG antibodies
Timeframe: Baseline (Day 1), assigned early follow-up timepoint (Day 8 or Day 45) and Day 181
Geometric mean concentration (GMC) of nasal RSV pre-fusion (preF) binding IgG antibodies
Timeframe: Baseline (Day 1), assigned early follow-up timepoint (Day 8 or Day 45) and Day 181
Geometric mean titers (GMT) of serum RSV-A neutralizing antibodies
Timeframe: Baseline (Day 1), assigned early follow-up timepoint (Day 8 or Day 45) and Day 181

Secondary (2)

Serum Geometric mean concentration (GMC) of clesrovimab
Urea-normalized GMC of clesrovimab in the nasal mucosa

Arms and interventions

Infants Receiving Clesrovimab (Enflonsia™)Experimental

Participants will receive a single injection of clesrovimab intramuscularly in the anterolateral thigh at a dose of 105 mg, at Visit 1 (Day 1).

Biologicals: Clesrovimab

Sites

1 site in 1 country

  • Emory Children's Center-Vaccine Research ClinicAtlanta, Georgia, United States